Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Stichel D, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682–694. doi:10.1016/S1470-2045(17)30155-9
   Web of Science ®Google Scholar
• Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 2000;38(1):45–52. doi:10.1016/S0920-1211(99)00066-2
   Web of Science ®Google Scholar
• Vignes JR, Sesay M, Rezajooi K, et al. Peritumoral edema and prognosis in intracranial meningioma surgery. J Clin Neurosci. 2008;15(7):764–768. doi:10.1016/j.jocn.2007.06.001
   Web of Science ®Google Scholar
• Sindou MP, Alaywan M. Most intracranial meningiomas are not cleavable tumors: anatomic-surgical evidence and angiographic predictibility. Neurosurgery. 1998;42(3):476–480. doi:10.1097/00006123-199803000-00007
   Web of Science ®Google Scholar
• Gill CM, Loewenstern J, Rutland JW, et al. Peritumoral edema correlates with mutational burden in meningiomas. Neuroradiology. 2021;63(1):73–80. doi:10.1007/s00234-020-02515-8
   Web of Science ®Google Scholar
• Gawlitza M, Fiedler E, Schob S, et al. Peritumoral brain edema in meningiomas depends on aquaporin-4 expression and not on tumor grade, tumor volume, cell count, or Ki-67 labeling index. Mol Imaging Biol. 2017;19(2):298–304. doi:10.1007/s11307-016-1000-7
   Web of Science ®Google Scholar
• Lambertz N, Hindy NE, Adler C, et al. Expression of aquaporin 5 and the AQP5 polymorphism A(−1364) C in association with peritumoral brain edema in meningioma patients. J Neurooncol. 2013;112(2):297–305. doi:10.1007/s11060-013-1064-z
   PubMed Web of Science ®Google Scholar
• Rutkowski R, Chrzanowski R, Trwoga M, et al. Expression of N-cadherin and β-catenin in human meningioma in correlation with peritumoral edema. Int J Neurosci. 2018;128(9):805–810. doi:10.1080/00207454.2018.1424153
   PubMed Web of Science ®Google Scholar
• Salokorpi N, Yrjänä S, Tuominen H, et al. Expression of VEGF and collagen XVIII in meningiomas: correlations with histopathological and MRI characteristics. Acta Neurochir. 2013;155(6):989–996. doi:10.1007/s00701-013-1699-8
   Web of Science ®Google Scholar
• Reszec J, Hermanowicz A, Rutkowski R, et al. Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema. Biomed Res Int. 2015;2015:646853. doi:10.1155/2015/646853
   PubMed Web of Science ®Google Scholar
• Hou J, Kshettry VR, Selman WR, et al. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013;35(6):E2. doi:10.3171/2013.8.FOCUS13301
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton IV W, Woody L, et al. Role of bevacizumab for treatment-refractory meningiomas: a systematic analysis and literature review. Surg Neurol Int. 2018;9(1):133. doi:10.4103/sni.sni_264_17
   PubMedGoogle Scholar
• Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44(7):912–920. doi:10.1016/j.ejca.2008.01.005
   Web of Science ®Google Scholar
• Lu VM, Ravindran K, Graffeo CS, et al. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes. J Neurooncol. 2019;144(2):239–248. doi:10.1007/s11060-019-03234-8
   PubMed Web of Science ®Google Scholar
• Pillay Smiley N, Alden T, Hartsell W, et al. Severe radiation necrosis successfully treated with bevacizumab in an infant with low-grade glioma and tumor-associated intractable trigeminal neuralgia. Pediatr Blood Cancer. 2016;63(9):1671–1673. doi:10.1002/pbc.26055
   Web of Science ®Google Scholar
• Pistolesi S, Boldrini L, Gisfredi S, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study. Neuropathol Appl Neurobiol. 2004;30(2):118–125. doi:10.1046/j.0305-1846.2003.00516.x
   Web of Science ®Google Scholar
• Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010;99(3):393–405. doi:10.1007/s11060-010-0343-1
   PubMed Web of Science ®Google Scholar
• Bitzer M, Opitz H, Popp J, et al. Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor. Acta Neurochir. 1998;140(4):333–340. doi:10.1007/s007010050106
   Web of Science ®Google Scholar
• Hawasli AH, Rubin J, Tran D, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74(3):136–141. doi:10.1055/s-0033-1336173
   PubMed Web of Science ®Google Scholar
• Alanin MC, Klausen C, Caye-Thomasen P, et al. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - A retrospective case series. Int J Neurosci. 2016;126(11):1002–1006. doi:10.3109/00207454.2015.1092443
   PubMed Web of Science ®Google Scholar
• Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22–39. doi:10.1136/jnnp.20.1.22
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13(10):1143–1150. doi:10.1093/neuonc/nor091
   PubMed Web of Science ®Google Scholar
• Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269–278. doi:10.1158/1078-0432.CCR-09-2439
   PubMed Web of Science ®Google Scholar
• Khasraw M, Holodny A, Goldlust SA, et al. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol. 2012;23(2):458–463. doi:10.1093/annonc/mdr148
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol. 2010;96(2):259–269. doi:10.1007/s11060-009-9957-6
   Web of Science ®Google Scholar
• Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg. 2011;114(6):1609–1616. doi:10.3171/2010.10.JNS101042
   PubMed Web of Science ®Google Scholar
• Abrams DA, Hanson JA, Brown JM, et al. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. J Clin Neurosci. 2015;22(1):35–39. doi:10.1016/j.jocn.2014.05.054
   Web of Science ®Google Scholar
• Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008;26(6):1012–1013. doi:10.1200/JCO.2007.15.1605
   PubMed Web of Science ®Google Scholar
• Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142–148. doi:10.1200/JCO.2010.30.2729
   PubMed Web of Science ®Google Scholar
• Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156–163. doi:10.1016/j.ijrobp.2008.10.043
   PubMed Web of Science ®Google Scholar
• Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173–180. doi:10.3171/2008.4.17492
   PubMed Web of Science ®Google Scholar
• Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. Apmis. 2011;119(12):831–843. doi:10.1111/j.1600-0463.2011.02764.x
   PubMed Web of Science ®Google Scholar
• Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000;46(4):938–947. doi:10.1097/00006123-200004000-00033
   PubMed Web of Science ®Google Scholar
• Panagopoulos AT, Lancellotti CLP, Veiga JCE, et al. Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol. 2008;89(1):73–87. doi:10.1007/s11060-008-9588-3
   Web of Science ®Google Scholar
• Spille DC, Sporns PB, Heß K, et al. Prediction of high-grade histology and recurrence in meningiomas using routine preoperative magnetic resonance imaging: a systematic review. World Neurosurg. 2019;128:174–181. doi:10.1016/j.wneu.2019.05.017
   PubMed Web of Science ®Google Scholar
• Bečulić H, Skomorac R, Jusić A, et al. Correlation of peritumoral brain edema with morphological characteristics and Ki67 proliferative index in resected intracranial meningiomas. Acta Clin Croat. 2019;58(1):42–49. doi:10.20471/acc.2019.58.01.06
   Web of Science ®Google Scholar
• van Nieuwenhuizen D, Slot KM, Klein M, et al. The association between preoperative edema and postoperative cognitive functioning and health-related quality of life in WHO grade I meningioma patients. Acta Neurochir. 2019;161(3):579–588. doi:10.1007/s00701-019-03819-2
   PubMed Web of Science ®Google Scholar
• Loewenstern J, Aggarwal A, Pain M, et al. Peritumoral edema relative to meningioma size predicts functional outcomes after resection in older patients. Oper Neurosurg. 2019;16(3):281–291. doi:10.1093/ons/opy107
   Web of Science ®Google Scholar
• Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16(6):829–840. doi:10.1093/neuonc/not330
   PubMed Web of Science ®Google Scholar
• Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–217. doi:10.1007/s11060-009-9948-7
   PubMed Web of Science ®Google Scholar